A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours
dc.contributor.author | Robbrecht, D. G. J. | |
dc.contributor.author | Lopez, J. | |
dc.contributor.author | Calvo, E. | |
dc.contributor.author | He, X. | |
dc.contributor.author | Hiroshi, H. | |
dc.contributor.author | Soni, N. | |
dc.contributor.author | Cook, Natalie | |
dc.contributor.author | Dowlati, A. | |
dc.contributor.author | Fasolo, A. | |
dc.contributor.author | Moreno, V. | |
dc.contributor.author | Eskens, F. | |
dc.contributor.author | de Bono, J. S. | |
dc.date.accessioned | 2020-11-16T07:49:15Z | |
dc.date.available | 2020-11-16T07:49:15Z | |
dc.date.issued | 2020 | en |
dc.identifier.citation | Robbrecht DGJ, Lopez J, Calvo E, He X, Hiroshi H, Soni N, et al. A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. Br J Cancer. 2020. | en |
dc.identifier.pmid | 33020594 | en |
dc.identifier.doi | 10.1038/s41416-020-01100-3 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623428 | |
dc.description.abstract | Background: This is a first-in-human study with TAS-119, an Aurora A kinase (AurA) inhibitor. Methods: Patients with advanced, refractory, solid tumours were enrolled into 5 dose escalation cohorts (70-300 mg BID, 4 days on/3 days off, 3 out of 4 weeks or 4 out of 4 weeks). The expansion part consisted of patients with small-cell lung cancer, HER2-negative breast cancer, MYC-amplified/?-catenin-mutated (MT) tumours or other (basket cohort). Results: In the escalation part (n = 34 patients), dose-limiting toxicities were one grade 3 nausea, two grade 2 and one grade 3 ocular toxicity and a combination of fatigue, ocular toxicity and nausea in one patient (all grade 2) at dose levels of 150, 200, 250 and 300 mg, respectively. Most frequent treatment-related adverse events were fatigue (32%), diarrhoea (24%) and ocular toxicity (24%). Toxicity grade ?3 in ?10% of patients were diarrhoea (15%) and increased lipase (12%). The maximum tolerated dose was 250 mg BID. Due to one additional grade 1 ocular toxicity, the RP2D was set at 200 mg BID (4 days on/3 days off, 3 out of 4 weeks), which was further explored in the expansion part (n = 40 patients). Target inhibition in paired skin biopsies was shown. Conclusions: TAS-119 has a favourable and remarkably distinct safety profile from other AurA inhibitors. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1038/s41416-020-01100-3 | en |
dc.title | A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours | en |
dc.type | Article | en |
dc.contributor.department | Erasmus MC Cancer Institute, Rotterdam, the Netherlands. | en |
dc.identifier.journal | British Journal of Cancer | en |
dc.description.note | en] |